BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders.

Autor: Tsoy E; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Erlhoff SJ; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Goode CA; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Dorsman KA; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Kanjanapong S; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Lindbergh CA; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., La Joie R; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Strom A; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Rabinovici GD; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA.; Department of Radiology and Biomedical Imaging University of California San Francisco San Francisco California USA., Lanata SC; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Miller BL; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Tomaszewski Farias SE; Department of Neurology University of California Davis Sacramento California USA., Kramer JH; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Rankin KP; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA., Possin KL; Department of Neurology, Memory and Aging Center University of California San Francisco San Francisco California USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (Amsterdam, Netherlands) [Alzheimers Dement (Amst)] 2020 Jun 21; Vol. 12 (1), pp. e12042. Date of Electronic Publication: 2020 Jun 21 (Print Publication: 2020).
DOI: 10.1002/dad2.12042
Abstrakt: Introduction: Composite scores based on psychometrically rigorous cognitive assessments are well suited for early diagnosis and disease monitoring.
Methods: We developed and cross-validated the Brain Health Assessment-Cognitive Score (BHA-CS), based on a brief computerized battery, in 451 cognitively normal (CN) and 399 cognitively impaired (mild cognitive impairment [MCI] or dementia) older adults. We investigated its long-term reliability and reliable change indices at longitudinal follow-up (N = 340), and the association with amyloid beta (Aβ) burden in the CN subgroup with Aβ positron emission tomography (N = 119).
Results: The BHA-CS was accurate at detecting cognitive impairment and exhibited excellent long-term stability. Reliable decline over one year was detected in 75% of participants with dementia, 44% with MCI, and 3% of CN. Among CN, the Aβ-positive group showed worse longitudinal performance on the BHA-CS compared to the Aβ-negative group.
Discussion: The BHA-CS is sensitive to cognitive decline in preclinical and prodromal neurodegenerative disease.
Competing Interests: No authors reported competing interests relevant to this study. Dr. La Joie has received research funding from the Alzheimer's Association. Dr. Rabinovici has received consulting fees or speaking honoraria from GE Healthcare, Axon Neurosciences, Merck, Eisai, Roche, and Genentech; grants from Avid Radiopharmaceuticals, Eli Lilly and Company, GE Healthcare, Life Molecular Imaging; and research funding from the National Institutes of Health (NIH), the Rainwater Charitable Foundation, and the Alzheimer's Association. Dr. Miller has received research funding from the NIH; serves as Medical Director for the John Douglas French Foundation; Scientific Director for the Tau Consortium; Director/Medical Advisory Board of the Larry L. Hillblom Foundation; Scientific Advisory Board Member for the National Institute for Health Research Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia (UK); and Board Member for the American Brain Foundation (ABF). Dr. Tomaszewski Farias has received research funding from the NIH. Dr. Kramer has received research funding from the NIH and the Larry L. Hillblom Foundation and royalties from Pearson Education, Inc. Dr. Rankin has received research funding from the NIH, Quest Diagnostics, the Rainwater Charitable Foundation, the Weill Family Foundation, and the Marcus Foundation. Dr. Possin has received research funding from the NIH, Quest Diagnostics, the Global Brain Health Institute, the Merck Foundation, and the Rainwater Charitable Foundation. No other disclosures were reported.
(© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of the Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: